The apparent antipsychotic action of the 5-HT2a receptor antagonist M100907 in a mouse model of schizophrenia is counteracted by ritanserin. (Rapid communication)

J Neural Transm (Vienna). 1997;104(4-5):561-4. doi: 10.1007/BF01277672.

Abstract

The apparent antipsychotic action of the selective 5-HT2a receptor antagonist M100907 in MK-801-treated NMRI mice was shown to be markedly counteracted by the 5-HT2a/2c receptor antagonist ritanserin. The mechanism of action and potential implications are discussed.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Antipsychotic Agents / antagonists & inhibitors*
  • Antipsychotic Agents / pharmacology*
  • Dizocilpine Maleate
  • Excitatory Amino Acid Antagonists
  • Fluorobenzenes / antagonists & inhibitors
  • Fluorobenzenes / therapeutic use*
  • Male
  • Mice
  • Mice, Inbred Strains
  • Motor Activity / drug effects
  • Piperidines / antagonists & inhibitors
  • Piperidines / therapeutic use*
  • Ritanserin / pharmacology*
  • Schizophrenia / chemically induced
  • Schizophrenia / physiopathology*
  • Serotonin Antagonists / pharmacology*

Substances

  • Antipsychotic Agents
  • Excitatory Amino Acid Antagonists
  • Fluorobenzenes
  • Piperidines
  • Serotonin Antagonists
  • Ritanserin
  • Dizocilpine Maleate
  • volinanserin